TECHNLOGIES

BROADSWORD

Advanced broad reach invasive antibody treatment

SAVIOR

Cell medicine aimed at recovery and prevention

THE HAMMER

Flagship antiviral that smashes molecular bonds

GUARDIAN

Immune system strengthener that prevents disease

BROADSWORD

Advanced broad reach invasive antibody treatment

Ribavirin (Virazole), 1-β-d-ribofuranosyl-1,2,4-triazole-3-carboxamide, is the first synthetic nucleoside analogue that has ever been reported to be active against a broad spectrum of RNA viruses (HCV, RSV, and influenza virus): “its antiviral spectrum was the broadest ever reported for a synthetic material that did not induce interferon” (315). Its principal mechanism of drug action, established shortly after the discovery of ribavirin (316), is the inhibition of inosine-5′-monophosphate (IMP) dehydrogenase, which converts IMP to xanthosine monophosphate (XMP) and thus accounts for the de novo biosynthesis of GTP (317). The inhibitory activity of ribavirin on the IMP dehydrogenase may contribute to the immunosuppressive effects of ribavirin (318).
 

Acyclovir may also be used for other virus infections as determined by your doctor. However, it does not work in treating certain virus infections, such as the common cold.

Acyclovir is available only with your doctor’s prescription.

This product is available in the following dosage forms:

  • Tablet
  • Suspension
  • Capsule
  • Powder for Solution
  • Solution

THE HAMMER

Flagship antiviral that smashes molecular bonds

Rapivab (peramivir) is an injectable anti-viral drug approved for the treatment of acute uncomplicated influenza in patients 2 years of age and older who have been symptomatic for no more than 2 days. This product is approved to treat Type A and B influenza; however, the majority of patients included in the studies were infected with type A, the most common in the U.S. The efficacy of Rapivab could not be established in patients with serious influenza requiring hospitalization.

Rapivab is not approved for the prevention of influenza.

Rapivab is not a substitute for early influenza vaccination on an annual basis.

SAVIOR

Cell medicine aimed at recovery and prevention

Tamiflu (oseltamivir phosphate) is an oral anti-viral drug approved for the treatment of acute, uncomplicated influenza in patients 2 weeks of age and older whose flu symptoms have not lasted more than two days. This product is approved to treat Type A and B influenza; however, the majority of patients included in the studies were infected with type A, the most common in the U.S. Efficacy of Tamiflu in the treatment of influenza in subjects with chronic cardiac disease and/or respiratory disease has not been established.

Tamiflu is also approved for the prevention of influenza in adults and children aged one year and older. Efficacy of Tamiflu for the prevention of influenza has not been established in immunocompromised patients.

Tamilfu is not a substitute for early influenza vaccination on an annual basis.

This product is available in the following dosage forms:

  • Tablet
  • Suspension
  • Capsule
  • Powder for Solution
  • Solution

GUARDIAN

Immune system strengthener that prevents disease

Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-stream, joint, and abdominal infections, and meningitis.[7] The drug is given intravenously (IV) or intramuscularly (IM) every 8–12 hours (two or three times a day), with dose and frequency varying by the type of infection, severity, and/or renal function of the person. Ceftazidime is also commonly prescribed off-label for nebulization in people with cystic fibrosis for the suppression of Pseudomonas aeruginosa in the lungs as well as the treatment of pulmonary exacerbations. Those with kidney disease are dosed less frequently.[7]

Ceftazidime is the first-line treatment for the tropical infection, melioidosis, an important cause of sepsis in Asia and Australia.[8][9]

Labeled indications include the treatment of patients with:

  • Pseudomonas aeruginosa infections
  • other Gram-negative, aerobic infections
  • neutropenic fever[10]

As a class, cephalosporins have activity against Gram-positive and Gram-negative bacteria. The balance of activity tips toward Gram-positive organisms for earlier generations; later generations of cephalosporins have more Gram-negative coverage. Ceftazidime is one of the few in this class with activity against Pseudomonas aeruginosa. It is not active against methicillin-resistant Staphylococcus aureus.